Haemonetics (NYSE:HAE) announced today that it agreed to sell its whole blood assets to GVS S.p.A for $67.1 million.

Haemonetics（纽约证券交易所：HAE）今天宣布，它同意以6710万美元的价格将其全血资产出售给GVS S.p.A。

GVS, a manufacturer of filter solutions for healthcare and life sciences, agreed to pay $44.6 million up front. The deal also includes up to $22.5 million in contingent earn-outs over the next four years.

医疗保健和生命科学过滤解决方案制造商GVS同意预付4460万美元。该交易还包括未来四年高达2250万美元的或有盈利。

Under the terms of the agreement, GVS acquires Haemonetics’ complete portfolio of proprietary whole blood collection, processing and filtration solutions. It also takes the company’s manufacturing facility in Covina, California, where certain of those products are produced. GVS also acquired related equipment and assets at the Boston-based company’s Tijuana, Mexico, manufacturing plant..

根据协议条款，GVS收购了Haemonetics专有全血采集、处理和过滤解决方案的完整组合。它还将公司位于加利福尼亚州科维纳的制造工厂作为生产基地。GVS还收购了该公司位于波士顿的墨西哥蒂华纳制造厂的相关设备和资产。。

Haemonetics previously outlined its plan to end the life of its blood inline collection, leading to the closure of its Covina facility.

Haemonetics之前概述了其终止血液在线采集寿命的计划，导致其Covina设施关闭。

This deal follows Haemonetics’ sale of its Fajardo, Puerto Rico, manufacturing operations to GVS in 2020. The companies have a long-term supply and development agreement dating back to that deal, too. It grants GVS exclusive rights to manufacture and supply the proprietary blood filters produced in Fajardo..

这项交易之前，Haemonetics于2020年将其位于波多黎各的Fajardo制造业务出售给GVS。两家公司也有一份长期供应和开发协议，可以追溯到那笔交易。它授予GVS独家制造和供应法贾多生产的专有血液过滤器的权利。。

Haemonetics expects the deal to close in the first quarter of calendar 2025. It plans to use proceeds for general corporate purposes and investments in growth initiatives. The company said it expects its Blood Center business to continue manufacturing and providing customers with its full line of apheresis solutions for automated blood collection..

Haemonetics预计该交易将于2025年第一季度完成。它计划将收益用于一般企业用途和增长计划投资。该公司表示，预计其血液中心业务将继续生产，并为客户提供全系列的自动采血单采解决方案。。

“As part of our long-range plan we are focused on portfolio evolution to enhance our leadership in commercial and non-commercial plasma and expand our presence in high-growth hospital markets,” said Chris Simon, Haemonetics’ president and CEO. “Our agreement with GVS stems from our long partnership and will enable a smooth transition for Haemonetics’ whole blood customers worldwide while supporting our company’s goals.”.

“作为我们长期计划的一部分，我们专注于投资组合的演变，以增强我们在商业和非商业血浆领域的领导地位，并扩大我们在高增长医院市场的影响力，”Haemonetics总裁兼首席执行官克里斯·西蒙（ChrisSimon）表示。“我们与GVS的协议源于我们的长期合作关系，将使Haemonetics的全球全血客户能够顺利过渡，同时支持我们公司的目标。”。